NervGen Pharma Corp. (NGEN.V)
| Previous Close | 2.0000 |
| Open | 2.0500 |
| Bid | 2.2000 x 0 |
| Ask | 2.2200 x 0 |
| Day's Range | 1.9800 - 2.2400 |
| 52 Week Range | 1.5000 - 3.9800 |
| Volume | |
| Avg. Volume | 95,358 |
| Market Cap | 155.939M |
| Beta (5Y Monthly) | 1.46 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Newsfile
NervGen Pharma Reports 2023 Year-End Financial Results and Operational Updates
Anticipated completion of enrollment of the chronic cohort in the Phase 1b/2a clinical trial in Q2 2024CA$23 million bought deal financing completed in March 2024 provides expected cash runway through Q3 2025 Fast Track designation granted by U.S. Food and Drug Administration (FDA) for NVG-291 in spinal cord injuryVancouver, British Columbia--(Newsfile Corp. - April 17, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) a clinical-stage biotech company dedicated to developing innovative so
- Newsfile
NervGen Completes $23 Million Bought Deal Financing
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.Vancouver, British Columbia--(Newsfile Corp. - March 28, 2024) - NervGen Pharma Corp. (TSXV: NGEN) ("NervGen" or the "Company") is pleased to announce the closing of its previously announced public offering (the "Offering") including the full exercise of the underwriters' over-allotment option for aggregate gross proceeds to the Company of C$23,011,788. The Offering was made pursuant to an underwri
- CNW Group
NERVGEN ANNOUNCES $20 MILLION BOUGHT DEAL OFFERING
NervGen Pharma Corp. ("NervGen" or the "Company") (TSXV: NGEN) is pleased to announce that it has entered into an agreement with a syndicate of underwriters led by Stifel Canada, Canaccord Genuity and PI Financial (collectively, the "Underwriters"), who have agreed to purchase, on a "bought deal" basis 8,515,000 units (the "Units") of the Company at a price of $2.35 per Unit, for aggregate gross proceeds of $20,010,250 (the "Offering").
